Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
3.0
Journals
JPM
Special Issues
New Approaches in Radiation Oncology
share announcement

New Approaches in Radiation Oncology

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Methodology, Drug and Device Discovery".

Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 3327

Special Issue Editor

Dr. Alba Fiorentino

E-Mail Website
Guest Editor
1. Associate Professor, Radiation Oncology, Department of Medicine, LUM University, Casamassima, BA, Italy
2. Director Diagnostic and Therapeutic Department, Chief of Radiation Oncology, General Regional Hospital "F. Miulli", Acquaviva delle Fonti, BA, Italy
Interests: radiation therapy for primary and secondary brain tumors, breast and prostate cancer; high tech radiotherapy (including radiosurgery and stereotactic radiotherapy); ablative radiation (including cardiac radioablation)

Special Issue Information

Dear Colleagues,

Radiation oncology stands at the forefront of personalized medicine, where cutting-edge innovations are reshaping the landscape of cancer treatment and not only. This Special Issue serves as a beacon guiding us through the exciting developments that are revolutionizing the way we cure patients.

Our goal is to showcase the latest innovations in radiation oncology, ranging from advanced imaging technologies and precision treatment planning to the integration of artificial intelligence. We are particularly interested in how these approaches can be tailored to meet the unique needs of individual patients.

This Special Issue will delve into the significance of biomarkers, genomics, and patient-centric care in predicting treatment outcomes and minimizing side effects. Authors are encouraged to contribute research, reviews, and perspectives that shed light on the transformative potential of personalized medicine within the realm of radiation oncology.

Dr. Alba Fiorentino
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • radiotherapy
  • oncology
  • radiosurgery
  • radioablation
  • stereotactic radiotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 1233 KiB  
Article
Improving Quality Assurance in a Radiation Oncology Using ARIA Visual Care Path
by Ilaria Bonaparte, Federica Fragnoli, Fabiana Gregucci, Roberta Carbonara, Fiorella Cristina Di Guglielmo, Alessia Surgo, Valerio Davì, Morena Caliandro, Giuseppe Sanfrancesco, Christian De Pascali, Alberto Aga, Chiara Indellicati, Rosalinda Parabita, Rosilda Cuscito, Pietro Cardetta, Maurizio Laricchia, Michele Antonicelli, Annarita Ciocia, Domenico Curci, Pietro Guida, Maria Paola Ciliberti and Alba Fiorentinoadd Show full author list remove Hide full author list
J. Pers. Med. 2024, 14(4), 416; https://doi.org/10.3390/jpm14040416 - 14 Apr 2024
Viewed by 1371
Abstract
Purpose: Errors and incidents may occur at any point within radiotherapy (RT). The aim of the present retrospective analysis is to evaluate the impact of a customized ARIA Visual Care Path (VCP) on quality assurance (QA) for the RT process. Materials and Methods: [...] Read more.
Purpose: Errors and incidents may occur at any point within radiotherapy (RT). The aim of the present retrospective analysis is to evaluate the impact of a customized ARIA Visual Care Path (VCP) on quality assurance (QA) for the RT process. Materials and Methods: The ARIA VCP was implemented in June 2019. The following tasks were customized and independently verified (by independent checks from radiation oncologists, medical physics, and radiation therapists): simulation, treatment planning, treatment start verification, and treatment completion. A retrospective analysis of 105 random and unselected patients was performed, and 945 tasks were reviewed. Patients’ reports were categorized based on treatment years period: 2019–2020 (A); 2021 (B); and 2022–2023 (C). The QA metrics included data for timeliness of task completion and data for minor and major incidents. The major incidents were defined as incorrect prescriptions of RT dose, the use of different immobilization systems during RT compared to the simulation, the absence of surface-guided RT data for patients’ positioning, incorrect dosimetric QA for treatment plans, and failure to complete RT as originally planned. A sample size of approximately 100 was able to obtain an upper limit of 95% confidence interval below 5–10% in the case of zero or one major incident. Results: From June 2019 to December 2023, 5300 patients were treated in our RT department, an average of 1300 patients per year. For the purpose of this analysis, one hundred and five patients were chosen for the study and were subsequently evaluated. All RT staff achieved a 100% compliance rate in the ARIA VCP timely completion. A total of 36 patients were treated in Period A, 34 in Period B, and 35 in Period C. No major incidents were identified, demonstrating a major incident rate of 0.0% (95% CI 0.0–3.5%). A total of 26 out of 945 analyzed tasks (3.8%) were reported as minor incidents: absence of positioning photo in 32 cases, lack of patients’ photo, and absence of plan documents in 4 cases. When comparing periods, incidents were statistically less frequent in Period C. Conclusions: Although the present analysis has some limitations, its outcomes demonstrated that software for the RT workflow, which is fully integrated with both the record-and-verify and treatment planning systems, can effectively manage the patient’s care path. Implementing the ARIA VCP improved the efficiency of the RT care path workflow, reducing the risk of major and minor incidents. Full article
(This article belongs to the Special Issue New Approaches in Radiation Oncology)
►▼ Show Figures

Figure 1

10 pages, 1824 KiB  
Communication
Differences in Radiosensitivity According to EGFR Mutation Status in Non-Small Cell Lung Cancer: A Clinical and In Vitro Study
by Hidekazu Tanaka, Masako Karita, Kazushi Ueda, Taiki Ono, Miki Kajima, Yuki Manabe, Koya Fujimoto, Yuki Yuasa and Takehiro Shiinoki
J. Pers. Med. 2024, 14(1), 25; https://doi.org/10.3390/jpm14010025 - 25 Dec 2023
Viewed by 1630
Abstract
Unlike drug selection, radiation parameters (field, dose) are not based on driver gene mutations in patients with metastatic non-small cell lung cancer (NSCLC). This study aimed to compare radiosensitivity in NSCLC with and without EGFR driver gene mutations using clinical and in vitro [...] Read more.
Unlike drug selection, radiation parameters (field, dose) are not based on driver gene mutations in patients with metastatic non-small cell lung cancer (NSCLC). This study aimed to compare radiosensitivity in NSCLC with and without EGFR driver gene mutations using clinical and in vitro data. The clinical study included 42 patients who underwent whole-brain radiotherapy for brain metastases from NSCLC; of these, 13 patients had EGFR mutation-positive tumors. The Kaplan–Meier method was used to calculate the cranial control rate without intracranial recurrence. In the in vitro study, colony formation and double-strand DNA breaks were examined in two EGFR mutation-negative and three EGFR mutation-positive NSCLC-derived cell lines. Colony formation was assessed 14 days after irradiation with 0 (control), 2, 4, or 8 Gy. DNA double-strand breaks were evaluated 0.5 and 24 h after irradiation. EGFR mutation-positive patients had a significantly better cranial control rates than EGFR mutation-negative patients (p = 0.021). EGFR mutation-positive cells formed significantly fewer colonies after irradiation with 2 or 4 Gy than EGFR mutation-negative cells (p = 0.002, respectively) and had significantly more DNA double-strand breaks at 24 h after irradiation (p < 0.001). Both clinical and in vitro data suggest that EGFR mutation-positive NSCLC is radiosensitive. Full article
(This article belongs to the Special Issue New Approaches in Radiation Oncology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop